Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

('Mediclinic', the 'Company' or the 'Group')

26 July 2017

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting ('AGM') held on 25 July 2017, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholdersby way of poll. The results of the poll for each resolution were as follows:

TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHHELD

ORDINARY RESOLUTIONS

1.

To receive the Company's financial statements and the reports by the Directors and auditors

643,346,097

87.26%

642,608,938

99.99%

211

0.01%

736,948

2.

To approve the Directors' Remuneration Report

643,346,097

87.26%

618,212,690

96.25%

24,075,900

3.75%

1,057,507

3.

To approve the amended Directors' Remuneration Policy

643,346,097

87.26%

614,711,926

95.95%

25,915,697

4.05%

2,718,474

4.

To declare a final dividend of 4.70 pence per ordinary share

643,346,097

87.26%

642,966,257

99.99%

211

0.01%

379,629

5.

To elect Jurgens Myburgh as a Director

643,346,097

87.26%

640,899,142

99.68%

2,060,463

0.32%

386,492

6.

To re-elect Danie Meintjes as a Director

643,346,097

87.26%

642,864,882

99.99%

94,723

0.01%

386,492

7.

To re-elect Dr Edwin Hertzog as a Director

643,346,097

87.26%

625,998,995

97.38%

16,833,567

2.62%

513,535

8.

To re-elect Jannie Durand as a Director

643,346,097

87.26%

612,105,167

95.26%

30,444,213

4.74%

796,717

9.

To re-elect Alan Grieve as a Director

643,346,097

87.26%

640,694,983

99.93%

445,220

0.07%

2,205,894

10.

To re-elect Seamus Keating as a Director

643,346,097

87.26%

641,082,006

99.99%

46,572

0.01%

2,217,519

11.

To re-elect Prof Dr Robert Leu as a Director

643,346,097

87.26%

641,083,644

99.99%

44,934

0.01%

2,217,519

12.

To re-elect Nandi Mandela as a Director

643,346,097

87.26%

642,901,226

99.99%

49,254

0.01%

395,617

13.

To re-elect Trevor Petersen as a Director

643,346,097

87.26%

632,937,299

98.72%

8,191,279

1.28%

2,217,519

14.

To re-elect Desmond Smith as a Director

643,346,097

87.26%

639,878,832

99.87%

836,521

0.13%

2,630,744

15.

To re-appoint PricewaterhouseCoopers LLP as auditors of the Company

643,346,097

87.26%

642,446,940

99.99%

3,656

0.01%

895,501

16.

To authorise the Audit and Risk Committee to determine the remuneration of the auditors

643,346,097

87.26%

642,417,589

99.98%

120,859

0.02%

807,649

17.

To authorise the Directors to make political donations

643,346,097

87.26%

566,825,468

89.04%

69,771,641

10.96%

6,748,988

18.

To authorise the Directors to allot ordinary shares

643,346,097

87.26%

527,047,324

82.04%

115,391,424

17.96%

907,349

SPECIAL RESOLUTIONS

19.

To authorise the Directors to dis-apply the statutory pre-emption rights

643,346,097

87.26%

583,771,316

91.13%

56,840,187

8.87%

2,734,594

20.

To authorise the Directors to dis-apply pre-emption rightsfor purposes of acquisitions or capital investments

643,346,097

87.26%

591,889,385

93.19%

43,253,058

6.81%

8,203,654

21.

To authorise the amendment to the Articles of Association

643,346,097

87.26%

641,126,245

99.99%

1,314

0.01%

2,218,538

22.

To approve the reduction in minimum notice period for general meetings (other than annual general meetings)

643,346,097

87.26%

617,065,427

96.43%

22,854,064

3.57%

3,426,606

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDERON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

ORDINARY RESOLUTIONS

TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTED WITHHELD

9.

To re-elect Alan Grieve as a Director

571,230,713

77.48%

568,579,599

99.92%

445,220

0.08%

2,205,894

10.

To re-elect Seamus Keating as a Director

571,230,713

77.48%

568,966,622

99.99%

46,572

0.01%

2,217,519

11.

To re-elect Prof Dr Robert Leu as a Director

571,230,713

77.48%

568,968,260

99.99%

44,934

0.01%

2,217,519

12.

To re-elect Nandi Mandela as a Director

571,230,713

77.48%

570,785,842

99.99%

49,254

0.01%

395,617

13.

To re-elect Trevor Petersen as a Director

571,230,713

77.48%

560,821,915

98.56%

8,191,279

1.44%

2,217,519

14.

To re-elect Desmond Smith as a Director

571,230,713

77.48%

567,763,448

99.85%

836,521

0.15%

2,630,744

Notes:

1.

Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the 'For' total.

2.

A vote 'Withheld' is not a vote in law and is not counted in the calculation of the votes 'For' or 'Against' a resolution.

3.

The Company's total ordinary shares in issue (total voting rights) as at 25 July 2017 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.

4.

As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 9 to 14) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

(a) the shareholders of the Company as a whole; and

(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection athttp://www.morningstar.co.uk/uk/NSM.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Company's website at www.mediclinic.com.

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

+44 (0)207 954 9600

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website:www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor:RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor:Simonis Storm Securities (Pty) Ltd

Mediclinic International plc published this content on 26 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 July 2017 06:40:08 UTC.

Original documenthttp://ir.mediclinic.com/phoenix.zhtml?c=145797&p=irol-rnsArticle&ID=2288795

Public permalinkhttp://www.publicnow.com/view/6138F45C9CD765AD00FFAE1A2496AAE51D0A95B1